Navigation Links
Gene screen patent leads to 'Deal of Distinction'

UChicagoTech, the University of Chicago's Office of Technology and Intellectual Property, has received a 2007 Deal of Distinction Award from the Licensing Executives Society of U.S.A. and Canada.

The award stems from an agreement signed in late 2005 between the University of Chicago and the Mayo Clinic. The deal licensed the UGT1A1 diagnostic screen that predicts a patient's risk of side effects from a standard first-line treatment for advanced cancers of the colon and rectum. Mark J. Ratain, M.D., the Leon O. Jacobson Professor of Medicine at the University of Chicago, and colleagues developed the UGT1A1 test.

UChicagoTech was the sole honoree in the industry-university-government transactions category. The society also presented Deal of Distinction Awards in four other categories. The awards were announced in connection with the LES annual meeting in Vancouver, British Columbia, Canada, earlier this month.

Colorectal cancer is the fourth most commonly diagnosed cancer in the United States, with more than 145,000 new cases each year. It accounts for nearly 60,000 deaths annually in this country alone. Many colorectal cancer patients receive a first-line treatment of irinotecan hydrochloride (Camptosar(r)). Still in its early phases of implementation, more than 5,000 patients are expected to receive the UGT1A1 test this year.

The UGT1A1 test lets doctors know in advance which patients will have severe side effects from the drug by revealing which patients have versions of a gene that helps metabolize the drug. Patients who are at risk receive reduced doses of irinotecan hydrochloride or are treated with other chemotherapy drugs.

"This is a living example of the new genetic personalized medicine at work," said Alan Thomas, Director of UChicagoTech.

Until the December 2005 deal between the University and Mayo Clinic, the UGT1A1 test had only been available to patients enrolled in studies at the University of Chicago. Through the licensing agreement, Mayo Clinic's reference laboratory, Mayo Medical Laboratories, made the test available to patients nationwide.

The Deal of Distinction Awards recognize transactions involving the licensing and transfer of intellectual property and creative and innovative solutions to business issues in contracts announced over the previous year. Awards are presented in five industry categories, including consumer products; chemicals, energy and materials; healthcare; and high technology.

"While a 2005 deal, the LES Deal of Distinction Award Committee supported this nomination given the element it felt was most distinctive, the promise by Mayo to broadly sublicense the intellectual property, was not completely fulfilled until 2006, when Mayo signed the first of several deals with several third parties," said the award citation. Revenue from Mayo Laboratories' testing and technology licensing supports medical education and research at Mayo Clinic.


Contact: Steve Koppes
University of Chicago

Related medicine news :

1. A sunscreen from the sea
2. Need for Colon cancer screening
3. The Use Of MRI For Screening Of Breast Cancer Questioned
4. Adopting Easier Methods To Screen Insulin Resistance
5. Early Screening For Cancer May Save Lives
6. Mobile Endoscopic Facilities For Health Screening
7. DNA biochip for genetic screening
8. Breast screening among diabetic women
9. Screening device for ovarian cancer
10. Fast screening for macular degeneration
11. Screening bypasses radical breast surgery
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... With Thanksgiving right around the corner, holiday travel season ... protect your family and vehicle. , According to the National Highway Traffic Safety Administration, ... is sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... it has been designated an Aetna Institute of Quality® Bariatric Surgery Facility for ... the quality and cost of health care services available to its members to ...
(Date:11/24/2015)... M.D. (PRWEB) , ... November 24, 2015 , ... ... new award for its exceptional customer service: the TrustDale certification. The award recognizes ... The Baltimore stone honing , tile and grout, and hard surface restoration ...
(Date:11/24/2015)... ... , ... Autism Speaks, the world’s leading autism science and advocacy organization, will ... generosity of people around the world. On December 1, supporters can make an online ... share the personal stories behind those gifts. , Just as Black Friday and ...
(Date:11/24/2015)... ... ... All her life, Don Peck’s mother wondered if she was a descendant of Samuel Fuller, ... After a 25-year search for information, Don and his aunt discovered that she was not, ... Turns out, it was Don’s father who was descended from not one, but four passengers ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology: